Akso Health Group Sponsored ADR (AHG)
NASDAQ:AHG
Want to see AHG full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Positive Factors
Revenue Growth
The company has demonstrated substantial revenue growth, indicating strong market demand and successful expansion efforts in healthcare services.
Negative Factors
Profitability Challenges
Severe profitability issues due to net losses undermine financial health, necessitating strategic changes to improve cost efficiency and revenue generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The company has demonstrated substantial revenue growth, indicating strong market demand and successful expansion efforts in healthcare services.
Read all positive factors
Akso Health Group Sponsored ADR (AHG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.37B
Dividend YieldN/A
Average Volume (3M)21.06K
Price to Earnings (P/E)―
Beta (1Y)-0.41
Revenue Growth75.04%
EPS Growth-679.87%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryFinancial - Credit Services
Share Statistics
EPS (TTM)-0.40
Shares Outstanding549,200,900
10 Day Avg. Volume27,668
30 Day Avg. Volume21,060
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)1.69
Price to Sales (P/S)22.76
P/FCF Ratio328.95
Enterprise Value/Market Cap0.10
Enterprise Value/Revenue9.51
Enterprise Value/Gross Profit-499.07
Enterprise Value/Ebitda-79.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Akso Health Group Sponsored ADR Business Overview & Revenue Model
Company Description
Akso Health Group operates a social e-commerce mobile platform in China. The company operates Xiaobai Maimai App, which offers food and beverage products, wine, cosmetic products, fashion and apparel, entertainment products, housewares, home appli...
How the Company Makes Money
Akso Health Group generates revenue through a diversified model that includes providing healthcare services such as traditional Chinese medicine consultations, wellness management programs, and integrated healthcare solutions. The company collabor...
Akso Health Group Sponsored ADR Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.78M | 2.41M | 13.18M | 6.00M | 1.75M |
| Gross Profit | -281.53K | 122.13K | 1.27M | 605.13K | 1.21M |
| EBITDA | -1.77M | -8.64M | -14.27M | -3.19M | -28.90M |
| Net Income | -134.98M | -9.46M | -1.36M | -16.85M | -34.83M |
Balance Sheet | |||||
| Total Assets | 214.95M | 142.02M | 20.46M | 62.81M | 31.69M |
| Cash, Cash Equivalents and Short-Term Investments | 176.23M | 85.17M | 7.92M | 18.43M | 15.13M |
| Total Debt | 81.74K | 0.00 | 0.00 | 0.00 | 10.00M |
| Total Liabilities | 15.80M | 3.59M | 11.62M | 50.52M | 14.41M |
| Stockholders Equity | 199.12M | 138.37M | 8.73M | 12.28M | 17.27M |
Cash Flow | |||||
| Free Cash Flow | 1.02M | 1.35M | -3.25M | -8.63M | 10.06M |
| Operating Cash Flow | 1.18M | 1.35M | -3.25M | -8.63M | 10.06M |
| Investing Cash Flow | -105.91M | -54.72M | 18.47M | -19.96M | -662.00 |
| Financing Cash Flow | 195.88M | 131.65M | -27.51M | 34.78M | -9.04M |
Akso Health Group Sponsored ADR Technical Analysis
Negative
2.00
Price Trends
2.18
Negative
1.81
Negative
1.72
Negative
Market Momentum
-0.12
Positive
32.60
Neutral
3.74
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AHG, the sentiment is Negative. The current price of 2 is below the 20-day moving average (MA) of 2.03, below the 50-day MA of 2.18, and above the 200-day MA of 1.72, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 32.60 is Neutral, neither overbought nor oversold. The STOCH value of 3.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AHG.
Akso Health Group Sponsored ADR Risk Analysis
Akso Health Group Sponsored ADR disclosed 55 risk factors in its most recent earnings report. Akso Health Group Sponsored ADR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
The approval of the China Securities Regulatory Commission, or the CSRC, may be required in connection with an offering under PRC rules, regulations, or policies, and, if required, we cannot predict whether or how soon we will be able to obtain such approval. As a result, both you and us fact uncertainty about future actions by the PRC government that could significantly affect our business, our listing on Nasdaq, financial condition and results of operations. Q1, 2023
Akso Health Group Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $1.37B | ― | -67.58% | ― | 75.04% | -679.87% | |
82 Outperform | $1.16B | 5.42 | 15.80% | 5.20% | 4.05% | 8.52% | |
72 Outperform | $328.30M | 4.55 | 14.37% | 8.86% | -7.69% | 48.72% | |
62 Neutral | $165.95M | 28.48 | 0.54% | 10.37% | -1.41% | -98.13% | |
55 Neutral | $310.35M | 1.87 | 14.78% | ― | -4.00% | -48.96% |
* Healthcare Sector Average
AHG
Akso Health Group Sponsored ADR
1.60
-0.01
-0.62%
YRD
Yiren Digital
1.90
-4.07
-68.19%
FINV
FinVolution Group
4.77
-3.34
-41.19%
LX
Lexinfintech Holdings
1.96
-5.95
-75.23%
FOA
Finance of America Companies
18.65
-2.89
-13.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―